Skip to main content
    L

    Ligand Pharmaceuticals Incorporated (LGND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $293.81
    -7.90 (-2.62%)

    Market Cap: $6.04B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Ligand Pharmaceuticals Incorporated (LGND) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ligand Pharmaceuticals (LGND) has a market cap of $6.04B and an enterprise value of $7.11B. Its trailing P/E of 64.7x is above its 10-year median of 23.8x.

    Total Valuation

    Enterprise value is 17.77% above the market cap, as debt exceeds cash.

    Market Cap$6.04B
    Enterprise Value$7.11B
    Latest price (Nov 17, 2026)$293.81

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.50% in the quarter ended Sep 30, 2026 and grew 4.10% a year over 2 years.

    Shares Outstanding19.96M
    Shares Change (YoY)+1.96%
    Shares Change (QoQ)-0.50%
    Share Count Growth (2Y CAGR)+4.10%

    Valuation Ratios

    Sales and book value multiples are 23.1x and 6.1x. Its year-end P/E ranged from 11.7x to 42.3x from 2016 to 2025.

    P/E Ratio64.7x
    Forward P/E30.3x
    P/S Ratio23.1x
    Forward P/S20.7x
    P/B Ratio6.1x
    P/TBV Ratio13.0x
    P/FCF Ratio64.7x
    P/OCF Ratio66.3x
    PEG Ratio3.8

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 184.9x EBITDA and 76.5x free cash flow.

    EV / Earnings138.1x
    EV / Sales28.0x
    EV / EBITDA184.9x
    EV / FCF76.5x

    Price Statistics

    The stock is up 46.28% over 52 weeks and trades 2.75% below its 50-day average.

    Beta (1Y)0.94
    52-Week Change+46.28%
    1-Month Change-1.17%
    3-Month Change+1.07%
    6-Month Change+41.40%
    5-Year Change+121.15%
    10-Year Change+237.15%
    Total Return (1Y)+46.28%
    Total Return (3Y CAGR)+71.90%
    Total Return (5Y CAGR)+12.83%
    Return vs SPY (1Y)+30.34%
    Max Drawdown (1Y)-14.70%
    Max Drawdown (3Y)-25.58%
    Sharpe Ratio (1Y)0.96
    Correlation with SPY (1Y)0.35
    50-Day Average$302.13
    200-Day Average$259.40
    52-Week Range$175.89 to $326.63
    RSI (14 Days)41.4
    Average Volume (20 Days)224.25K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.22x current liabilities, and total debt is 1.17x shareholder equity.

    Current Ratio1.22x
    Quick Ratio1.19x
    Debt / Equity1.17x
    Debt / EBITDA30.08x
    Debt / FCF12.45x
    Interest Coverage0.15x

    Returns and Efficiency

    Return on invested capital is 0.06% over the last 12 months, against a 5-year average of 2.32%.

    Return on Equity (ROE)5.35%
    Return on Assets (ROA)2.30%
    Return on Invested Capital (ROIC)0.06%
    ROE (5Y Average)4.11%
    ROA (5Y Average)2.84%
    ROIC (5Y Average)2.32%
    Asset Turnover0.14x
    Inventory Turnover0.98x
    Receivables Turnover3.38x
    Cash Conversion Cycle278 days

    Taxes

    Income tax took 2.41% of pretax income over the last 12 months.

    Income Tax (TTM)$1.27M
    Effective Tax Rate2.41%

    Scores

    LGND has an Altman Z-Score of 3.28, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.28
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $253.83M over the last 12 months is up 1.03% from the 12 months before.

    Revenue$253.83M
    Revenue Growth (YoY)+1.03%
    Gross Profit$241.70M
    Operating Income$24.04M
    Pretax Income$52.73M
    Net Income$51.46M
    Reported EPS (TTM)$4.54

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 42.94% of the $2.24B in total assets.

    Cash and Equivalents$55.96M
    Total Debt$1.13B
    Net Debt$1.07B
    Net Debt Per Share$53.72
    Working Capital$107.67M
    Shareholder Equity$961.76M
    Book Value Per Share$48.18
    Tangible Book Value$451.86M
    Tangible Book Per Share$22.64
    Total Assets$2.24B
    Total Liabilities$1.28B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $405.00K of capital spending, operating cash flow left $90.63M of free cash flow.

    Operating Cash Flow$91.03M
    Capital Expenditures$405.00K
    Free Cash Flow$90.63M
    FCF Per Share$4.55
    Depreciation and Amortization$38.69M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 9.47%, against a 5-year average of 11.08%.

    Gross Margin95.22%
    Operating Margin9.47%
    Pretax Margin20.77%
    Net Margin20.27%
    FCF Margin35.70%
    Gross Margin (5Y Average)85.46%
    Operating Margin (5Y Average)11.08%
    Net Margin (5Y Average)18.08%

    Growth

    Revenue grew 10.96% a year over 3 years, and EPS 14.98% a year.

    Revenue Growth (3Y CAGR)+10.96%
    Revenue Growth (5Y CAGR)+10.39%
    EPS Growth (3Y CAGR)+14.98%
    EPS Growth (5Y CAGR)+8.30%
    FCF Growth (3Y CAGR)-25.84%
    FCF Growth (5Y CAGR)-0.49%
    Operating Income Growth (3Y CAGR)+138.11%
    Book Value Per Share Growth (2Y CAGR)+10.16%
    Tangible Book Per Share Growth (2Y CAGR)+39.19%

    Revenue and profit by year

    Dividends and Yields

    LGND does not pay a dividend. Its free cash flow yield is 1.55%.

    Earnings Yield1.55%
    FCF Yield1.55%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-6 reverse split on Nov 22, 2010.

    Last Split DateNov 22, 2010
    Split TypeReverse split
    Split Ratio1:6

    Peer Position

    Against 3 similar companies, LGND has the 3rd highest P/E.

    P/E Ratio64.7x vs 87.1x median
    P/S Ratio23.1x vs 8.6x median
    ROIC0.06% vs -36.34% median
    Revenue Growth (Trailing 4 Quarters, YoY)+1.03% vs +14.26% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 19.70% and EPS growth at 32.79% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+19.70%
    EPS Growth Forecast (2Y CAGR)+32.79%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LGND

    What is LGND's market cap?

    Ligand Pharmaceuticals has a market cap of $6.04B. Its enterprise value, which adds debt and subtracts cash, is $7.11B.

    What is LGND's P/E ratio?

    Ligand Pharmaceuticals has a trailing P/E ratio of 64.7x and a forward P/E of 30.3x.

    How many shares of LGND are outstanding?

    Ligand Pharmaceuticals has 19.96M shares outstanding. The count is up 1.96% from a year earlier.

    Does LGND pay a dividend?

    No. Ligand Pharmaceuticals does not pay a dividend.

    How much debt does LGND have?

    Ligand Pharmaceuticals has $1.13B of total debt and $55.96M of cash and equivalents, a net debt position of $1.07B.